Comparative Pharmacology
Head-to-head clinical analysis: INDIUM IN 111 PENTETREOTIDE KIT versus QUADRAMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDIUM IN 111 PENTETREOTIDE KIT versus QUADRAMET.
INDIUM IN-111 PENTETREOTIDE KIT vs QUADRAMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In-111 pentetreotide binds to somatostatin receptors, particularly subtypes 2 and 5, allowing scintigraphic localization of primary and metastatic neuroendocrine tumors bearing these receptors.
Samarium Sm 153 lexidronam is a radiolabeled agent that localizes to areas of osteoblastic bone activity. The samarium-153 isotope emits beta particles and gamma photons, delivering radiation to the bone and surrounding tissues. This results in the destruction of malignant cells in bone metastases.
111 MBq (3 mCi) indium In-111 pentetreotide administered intravenously over 1 minute; single dose for planar and SPECT imaging.
1.0 mCi/kg (37 MBq/kg) intravenously as a single dose.
None Documented
None Documented
Terminal half-life approximately 24 hours (range 22-26 hours), allowing imaging up to 24-48 hours post-injection
Terminal half-life: 6–8 hours (prolonged in renal impairment; may exceed 20 hours in CrCl <30 mL/min).
Renal: 80-90% unchanged within 24 hours; Fecal: 5-10%
Renal: 65% as unchanged drug; biliary/fecal: 20% as metabolites; remainder as other minor metabolites.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical